Last Update 05 Jun 26

CAH: Theranostics Expansion And Raised Guidance Will Support Future Upside

Narrative Update on Cardinal Health

The updated analyst price target for Cardinal Health has shifted modestly, with a small adjustment in the implied future P/E multiple to $29.42 as analysts weigh a mix of recent target cuts and one upward revision, along with ongoing initiation coverage.

Analyst Commentary

Recent Street research on Cardinal Health shows a mix of caution and support, with several target trims alongside one price target increase and a new bullish initiation. For you as an investor, this translates into a debate that centers on execution risk, earnings durability, and how much you should be willing to pay for the stock.

Bullish Takeaways

Bullish analysts lifting their price targets or starting coverage with a positive view are signaling confidence that Cardinal Health can justify a higher P/E multiple over time through execution on its core distribution and services businesses.
The bullish initiation suggests some research desks see the current valuation as reasonable relative to the company’s earnings profile, with room for upside if management delivers on operational goals.
The modest price target increase from one firm indicates that certain analysts are willing to give Cardinal Health more credit for its potential to sustain or improve profitability, even as others turn more cautious.
Supportive commentary around the stock often focuses on Cardinal Health’s scale and role in healthcare distribution, which some view as a foundation for steady, if unspectacular, earnings contribution to justify current valuation levels.

Bearish Takeaways

Several bearish analysts have lowered their price targets, reflecting concern that the prior valuation may have been too rich relative to Cardinal Health’s execution risks and earnings track record.
Target cuts from larger firms such as JPMorgan highlight worries that any missteps in cost control, contracts, or capital allocation could make it harder for the company to support higher P/E assumptions.
The cluster of downward revisions points to skepticism about how much earnings growth is realistic, which can cap how much multiple expansion some analysts are willing to assign to the stock.
Overall, the cautious camp appears focused on the possibility that Cardinal Health may need to show clearer, consistent progress on margins and growth initiatives before justifying more aggressive valuation targets.

What's in the News

Cardinal Health reported Q3 fiscal 2026 adjusted EPS of US$3.17, more than 13% above analyst estimates, with revenue of US$60.94b that was 11% higher year over year but about 2.1% below market expectations. Management raised full year adjusted EPS guidance to US$10.70 to US$10.80 and lifted adjusted free cash flow guidance, while recording an 18% increase in non GAAP operating earnings and a US$184m goodwill impairment tied to the Navista business. (Source: Cardinal Health Beats Q3 EPS Estimates, Raises Fiscal 2026 Guidance Despite Revenue Miss)
The company repurchased US$250m of stock in Q3, bringing total fiscal 2026 buybacks to US$1.0b and completing the repurchase of 11,719,964 shares, or 4.87%, under the program announced on June 8, 2023. (Source: Cardinal Health Beats Q3 EPS Estimates, Raises Fiscal 2026 Guidance Despite Revenue Miss; Key Developments)
Cardinal Health announced a quarterly dividend of US$0.5158 per share, payable July 15, 2026, with an ex dividend and record date of July 1, 2026. (Source: Key Developments)
The company is expanding Actinium 225 production at its Center for Theranostics Advancement in Indianapolis, adding a high capacity line that substantially increases cGMP compliant output for investigational and future commercial therapies. Since late 2024, weekly Ac 225 output has roughly quadrupled and Cardinal Health reports support for more than 15 clinical trials worldwide using this material. (Source: Key Developments)
Cardinal Health issued a voluntary recall of select lots of Webcol Large Alcohol Prep Pads in the U.S., Puerto Rico, and Japan due to microbial contamination with Paenibacillus phoenicis, citing a reasonable probability of local or systemic infections in at risk patients, including those receiving chemotherapy or with poorly controlled diabetes. (Source: Key Developments)

Valuation Changes

Fair Value: The model fair value estimate remains unchanged at $245.27, indicating no revision to the underlying intrinsic value output.
Discount Rate: The discount rate is effectively unchanged at 7.11%, so the required rate of return used in the valuation framework is stable.
Revenue Growth: The assumed revenue growth rate is effectively flat, edging from 7.83% to 7.83%, a move too small to materially affect the model.
Net Profit Margin: The assumed net profit margin is also essentially unchanged, moving from 0.72% to 0.72%, with only a minor model-level adjustment.
Future P/E: The future P/E multiple assumption has slipped slightly from 29.55x to 29.42x, reflecting a modestly lower valuation multiple applied to projected earnings.

7 views

Key Takeaways

Growth in pharmaceuticals and specialty distribution is driven by demographic trends, with diversification into specialty and home healthcare strengthening future earnings potential.
Efficiency gains from automation and portfolio optimization are expected to improve margins, cash flow, and profit resilience amid ongoing healthcare industry changes.
Increasing regulatory pressures, competitive threats, customer dependence, and evolving reimbursement risks could compress margins and constrain Cardinal Health's long-term growth prospects.

Catalysts

About Cardinal Health

Operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally.What are the underlying business or industry changes driving this perspective?

Cardinal Health is well-positioned to benefit from increasing global demand for pharmaceuticals and medical supplies driven by an aging population and the rising prevalence of chronic diseases, which is leading to robust pharmaceutical volumes and consistent revenue growth in core and specialty distribution-positively impacting future top-line revenue.
The company's investments in automation, advanced supply chain technology, and new distribution centers are expected to deliver long-term operational efficiencies and cost savings, supporting improved net margins and free cash flow as healthcare shifts to value-based and outpatient models.
Strategic expansion into higher-margin specialty businesses, including acquisitions in multi-specialty MSO platforms (e.g., Solaris Health), specialty pharma, and biopharma solutions, should accelerate long-term profit growth, diversify revenue streams, and enhance overall earnings resilience.
The strong performance and continued investment in Other growth businesses such as at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics aligns with the growing trend of outpatient and home healthcare-underpinning diversified revenue growth and supporting margin expansion.
Ongoing efforts to optimize the generic drug portfolio and scale Cardinal Health-branded medical products are yielding higher profitability versus branded counterparts and are expected to further enhance gross profit and operating margins, reinforcing long-term earnings growth.

Cardinal Health Earnings and Revenue Growth

Cardinal Health Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Cardinal Health's revenue will grow by 7.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 0.6% today to 0.7% in 3 years time.
Analysts expect earnings to reach $2.3 billion (and earnings per share of $10.79) by about June 2029, up from $1.6 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $1.9 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 29.5x on those 2029 earnings, down from 30.4x today. This future PE is greater than the current PE for the US Healthcare industry at 23.5x.
Analysts expect the number of shares outstanding to decline by 1.92% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Increasing government regulation and pricing scrutiny, as referenced by the company managing through "regulatory uncertainty" and "the implementation of tariffs," could compress distribution margins and impact net margins and earnings over the long term.
Heightened competition from peers and potential loss or expiration of major customer contracts, as seen in the "previously announced customer contract expiration," could limit future revenue growth and pressure operating earnings.
Ongoing tariff headwinds and global supply chain risks remain substantial, with GMPD segment guidance assuming a "$50 million to $75 million headwind to our results in fiscal '26 from tariffs," while further volatility could drive increased costs and impact consolidated margins and net income.
Increasing consolidation and vertical integration among healthcare providers, payers, and retailers-combined with Cardinal's dependence on major customer relationships highlighted by the impact of contract expirations-may compress revenue streams and erode gross profit over time.
Potential reimbursement changes and government bidding programs, such as referenced "potential changes in the reimbursement environment" and "competitive bidding coming back," specifically in the at-Home Solutions segment, could reduce top-line growth and profitability within key business lines.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $245.27 for Cardinal Health based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $275.0, and the most bearish reporting a price target of just $215.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $314.4 billion, earnings will come to $2.3 billion, and it would be trading on a PE ratio of 29.5x, assuming you use a discount rate of 7.1%.
Given the current share price of $201.74, the analyst price target of $245.27 is 17.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Cardinal Health?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

CAH: Core Pharmaceutical Trends And Automation Will Shape Upcoming Earnings Performance